Seeking Alpha

Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces....

Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces. The drug attempts to prevent a worsening of Alzheimer's by blocking production of a protein believed to contribute to the disease. Eli Lilly (LLY) has reported positive Phase III trial results for its solanezumab Alzheimer's drug, when administered to patients with mild symptoms.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)